|
Related Articles |
Assessment of lisdexamfetamine dimesylate stability and identification of its degradation product by NMR spectroscopy.
Drug Dev Ind Pharm. 2018 Sep 20;:1-21
Authors: Carlos G, Magalhães A, Isler AC, Comiran E, Fröehlich PE
Abstract
Lisdexamfetamine dimesylate (LDX), a long-acting prodrug stimulant indicated for the treatment of the attention-deficit/hyperactivity disorder (ADHD), was subjected to forced degradation studies by acid and alkaline hydrolysis and the degradation profile was studied. To obtain between 10-30% of degraded product, acid and alkaline conditions were assessed with solutions of 0.01 M, 0.1 M, 0.5 M and 1 M of DCl and NaOD. These solutions were analyzed through 1H NMR spectra. Acid hydrolysis produced no degradation in 0.01 M and 0.1 M DCl and 4.38%, 9.69% and 17.75% of degradation LDX, respectively, in 0.5 M, 1 M (4h) and 1 M (4 + 12 h) DCl. And alkaline hydrolysis produced no degradation in 0.01 M and 0.1 M DCl and a degradation LDX extension of 8.5%, 14.30% and 22.91%, respectively, in 0.5 M, 1 M (4h) and 1 M (4 + 12 h) NaOD. LDX solutions subjected to 1M (4 + 12 h) acid and alkaline hydrolysis were evaluated by NMR spectra (1H NMR, 13C NMR, HSQC and HMBC). LDX degradation product (DP) was identified and its structure elucidated as a diastereoisomer of LDX: (2R)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl] hexanamide without their physical separation.
PMID: 30231652 [PubMed – as supplied by publisher]
via https://www.ncbi.nlm.nih.gov/pubmed/30231652?dopt=Abstract

